Z Squared (ZSQR) Q4 2024 earnings summary

Executive summary

• Focused on cell therapy platforms for cancer, autoimmune, and infectious diseases, with a technology division enhancing operational capabilities through AI and automation.

• Operates through subsidiaries, including SNAP Biosciences and GEAR Therapeutics, with recent expansion into technology assets.

• Completed a 20-1 reverse stock split on December 31, 2024.

Financial highlights

• Net loss for 2024 was $10.88 million, compared to $21.27 million in 2023.

• Operating expenses decreased to $10.05 million in 2024 from $21.49 million in 2023, mainly due to lower R&D and legal costs.

• Cash balance at year-end 2024 was $532,885, down from $1.47 million at year-end 2023.

• Accumulated deficit reached $98.23 million as of December 31, 2024.

• Minimal revenue generated; company does not expect significant revenue in the next year.

Outlook and guidance

• Management does not expect significant revenue for at least the next year as drug development continues.

• Plans to raise additional capital through equity transactions and strategic partnerships.

• Substantial doubt exists about the ability to continue as a going concern due to recurring losses and limited cash.